Category
Blog
-
2023
-
Integrated Drug Discovery CRO Services for Pharmaceutical R&D
-
FDA Approves Novartis Treatment Combination for Pediatric Glioma
-
Paxlovid Gets Advisory Panel Support for Full FDA Approval
-
Mayo Clinic cancer expert highlights advancements in treating multiple myeloma
-
Xtandi Shows Promise in Prostate Cancer Trial
-
FDA Green Lights Clinical Trial of Low-Dose Psilocybin
-
AbbVie Hits Snag for Parkinson’s Disease Candidate
-
FDA Offers Advice on NDAs for Postoperative Local Anesthetics
-
Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of FPI-2059, a Targeted Alpha Therapy (TAT) for the Treatment of Solid Tumors Expressing NTSR1
-
US FDA declines to approve AbbVie’s Parkinson’s disease therapy